Status:
UNKNOWN
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Lead Sponsor:
University of Athens
Conditions:
Diabetes
Clopidogrel Resistance
Eligibility:
All Genders
18+ years
Brief Summary
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate th...
Detailed Description
In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Lig...
Eligibility Criteria
Inclusion
- type 2 diabetic patients with coronary artery disease, documented by coronary angiography,
- both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study
Exclusion
- abnormal renal function (creatinine\> 2.5 mg / dl),
- hepatic failure (bilirubin\> 2 mg / dl),
- active malignancy,
- patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd,
- patients with a history of hemorrhagic mood,
- patients with thrombocytopenia (PLTs \< 100x109 / L) and
- anemia (HCT \<28%).
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04027712
Start Date
January 1 2014
End Date
December 31 2021
Last Update
July 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General & University Hospital "Attikon"
Chaïdári, Attica, Greece, 12462